期刊文献+

复方单硝酸异山梨醇酯缓释片人体生物等效性研究

Bioequivalence studies of compound isosorbide-mononitrate sustained release tablets in healthy volunteers
下载PDF
导出
摘要 目的 :评价试验制剂复方单硝酸异山梨醇酯缓释片 (T)与参比制剂单硝酸异山梨醇酯缓释片和阿司匹林肠溶片 (R)的生物等效性 ,以及缓释制剂释放特点、稳态血浓度和波动度。方法 :采用高效液相色谱法分别测定单剂和多剂交叉给药单硝酸异山梨醇酯和阿司匹林代谢物水杨酸经时血浓度 ,计算药物动力学参数 ,并进行方差分析和双单侧t检验。结果 :单剂给药试验制剂和参比制剂单硝酸异山梨醇酯半衰期 (t1 2 )分别为 8.3± 0 .6、8.2± 0 .6h ,血浓度峰值 (Cmax)分别为 0 .5 1± 0 .0 9、 0 .5 3±0 .0 9mg·L-1,达峰时间 (tmax)分别为 4 .8± 0 .4、4 .6± 0 .3h ,药时曲线下面积 (AUC0 -t)分别为 4 .90±0 .6 1、5 .2± 0 .8mg·h-1·L-1,相对生物利用度 (F)为(96 .1± 10 .8) % ;试验制剂和参比制剂阿司匹林代谢物水杨酸t1 2 分别为 2 .4± 0 .3、2 .5± 0 .3h ,Cmax分别为 3.4± 0 .5、3.0± 0 .4mg·L-1,tmax分别为 1.7±0 .2h和 4 .9± 0 .3h ,AUC0 -t分别为 13.4± 2 .5和13.0± 2 .5mg·h-1·L-1,以水杨酸计阿司匹林F为(10 3.6± 9.6 ) %。多剂给药试验制剂和参比制剂单硝酸异山梨醇酯Cmax 分别为 0 .6 8± 0 .14、0 .6 7±0 .13mg·L-1,Cmin 分别为 0 .17± 0 .0 3、 0 .17±0 .0 4mg·L-1,波动系数 (DF)? AIM: To compare the bioequivalence of test formulation compound isosorbide mononitrat sustained release tablets (T) and reference formulation isosorbide mononitrat sustained release tablets and aspirin enteric coated tablets(R), and to evaluate release characteristics and degree of fluctuation of test formulation. METHODS: A high performance liquid chromatography method was used to determine the time plasma isosorbide mononitrat and salicylic acid concentrations after a single and multiple oral doses of test and reference formulations in 18 healthy volunteers respectively in an open randomized two way crossover experimental test. The pharmacokinetic parameters as well as relative bioavailability were calculated with DAS practical pharmacokinetic programme, variance and two one side t test were analyzed. RESULTS: The t 1/2 , C max , t max , AUC 0-t for isosorbide mononitrat after a single oral dose of test and reference were 8.3 ± 0.6 and 8.2 ± 0.6 h , 0.51 ± 0.09 and 0.52 ± 0.09 mg·L -1 , 4.8 ± 0.4 and 4.6 ± 0.3 h , 4.9 ± 0.6 and 5.2 ± 0.8 mg·h -1 ·L -1 , respectively, and the bioavailability of test was ( 96.1 ± 10.8 )%, and for salicylic acid, they were 2.4 ± 0.3 and 2.5 ± 0.3 h , 3.4 ± 0.5 and 3.0 ± 0.4 mg·L -1 , 1.7 ± 0.2 and 4.9 ± 0.3 h , 13.4 ± 2.5 and 13.0 ± 2.5 mg·h -1 ·L -1 , respectively, and the bioavailability of test was ( 103.6 ± 9.6 )%. After multiple oral doses of test and reference, the C max , C min , DF for isosorbide mononitrat were 0.68 ± 0.14 and 0.67 ± 0.13 mg·L -1 , 0.17 ± 0.03 and 0.17 ± 0.04 mg·L -1 , (136±36)% and (140±42)%, respectively. CONCLUSION: The compound isosorbide mononitrat sustained release tablets and isosorbide mononitrat sustained release tablets and aspirin enteric coated tablets are bioequivalent; the isosorbide mononitrat of test formulation has sustained release characteristics.
出处 《中国临床药理学与治疗学》 CAS CSCD 2004年第3期340-344,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 单硝酸异山梨醇酯 阿司匹林 水杨酸 生物等效性 高效液相色谱法 isosorbide mononitrate aspirin salicylic acid bioequivalence high performance liquid chromatography
  • 引文网络
  • 相关文献

参考文献3

二级参考文献8

共引文献24

相关主题

;
使用帮助 返回顶部